{"id":49337,"date":"2026-03-26T17:03:15","date_gmt":"2026-03-26T17:03:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/49337\/"},"modified":"2026-03-26T17:03:15","modified_gmt":"2026-03-26T17:03:15","slug":"novo-nordisks-strategic-appointment-blending-candy-insights-with-obesity-treatment","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/49337\/","title":{"rendered":"Novo Nordisk&#8217;s Strategic Appointment: Blending Candy Insights with Obesity Treatment"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Novo Nordisk has strategically appointed Poul Weihrauch, the CEO of U.S. candy giant Mars, as a board observer. This move comes as the pharmaceutical company aims to bolster its position in the competitive U.S. obesity market.<\/p>\n<p>The announcement was made during Novo Nordisk&#8217;s annual general meeting, which also saw the election of pharmaceutical experts Jan van de Winkel and Ramona Sequeira to the board. Last year, the company underwent a leadership shake-up, replacing its CEO and restructuring its board to improve its U.S. market strategies.<\/p>\n<p>Under the new management, Novo Nordisk is focusing on enhancing its consumer credentials through various channels such as telehealth, retail partnerships, and direct-to-consumer access for its weight-loss drug, Wegovy. The company&#8217;s efforts are aligning with its main competitor, Eli Lilly and Co, as they aim to capture the consumer-driven obesity market.<\/p>\n<p>&#13;<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Novo Nordisk has strategically appointed Poul Weihrauch, the CEO of U.S. candy giant Mars, as a board&hellip;\n","protected":false},"author":2,"featured_media":36965,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[27571,27570,276,552,272,27569,27516,360,1910,3388],"class_list":["post-49337","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-board-restructuring","tag-consumer-driven-strategy","tag-eli-lilly","tag-mars","tag-novo-nordisk","tag-obesity-market","tag-poul-weihrauch","tag-telehealth","tag-wegovy","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116296561673747677","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/49337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=49337"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/49337\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/36965"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=49337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=49337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=49337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}